Health insurance company Aetna has announced that it will start selling its own version of its popular drug allergy treatment, EpiPen, in 2018.
The company said it will be the first in the industry to begin selling the drug, called EpiMed, for allergy sufferers and their caregivers.
Aetnam will start stocking EpiPens at retail stores in the United States in 2018 and across the country in 2019.
It’s the first time Aetnas EpiPad drug is on the market, the company said.
EpiPatient, a company that sells the allergy medication, will also be part of the new drug lineup.
EpiMed is a long-acting injection that is used for managing severe allergic reactions to many types of medications.
It’s also used to treat anaphylaxis, which is an allergic reaction that causes the body’s immune system to attack a substance.
The drug can also treat the symptoms of multiple sclerosis, a neurological disorder that affects nerve cells in the brain.
It is also used for treating severe asthma, which affects the lungs.
It can be used to fight hay fever and for treating bronchitis.
Aetna will also offer EpiTaps for children.
The device can be administered by a nurse practitioner, or a pharmacist.
Epidemiologists at the University of Washington and Johns Hopkins University found that EpiPar is the most commonly prescribed allergy medication in the US, with more than 9 million prescriptions issued in 2017, according to the U.S. Centers for Disease Control and Prevention.
In a statement, Aetan said it plans to make EpiPod available for prescription in 2018, and that it would work with pharmacy benefit managers to make the product available for purchase.AEPs first-ever allergy drug, Epitest, is a nasal spray that was introduced in 2015.
The company has previously released the drug for sale to Medicaid in states that are covered by the Affordable Care Act.